DEALS

Zhong Lun Advises on Taimei’s IPO on the Main Board of The Stock Exchange of Hong Kong Limited

Release time：2024-10-08 Voice Announcements

On October 8, 2024, Zhejiang Taimei Medical Technology Co., Ltd. (2576.HK) announced the closing of its initial public offering and listing on the Main Board of The Stock Exchange of Hong Kong Limited, raising net proceeds of approximately HKD 259.5million prior to the exercise of the over-allotment option. Morgan Stanley and CICC acted as the joint sponsors for the listing.

Taimei designs and provides industry-specific software and digital services to a variety of stakeholders in the pharmaceutical and medical device industry. It is the largest digital solution provider for pharmaceutical and medical device R&D and commercialization in China in terms of revenue in 2023, according to CIC.

Zhong Lun Law Firm acted as the PRC legal advisor to the joint sponsors in this listing. The project team was led by partners Anthony Zhao and William Jia, and included associates Cynthia Yuan, Crystal Li, Oren Dong, Stella Zhou, etc. In addition, partner George Cheng provided significant support for the listing.

Previous：Zhong Lun Advises on CR Beverage’s IPO in Hong Kong Next：Zhong Lun Assists Several International Non-Profit Organizations in Building Personal Information Compliance Systems and Completing Standard Contract Filings

Print articles from Zhong Lun

Insights >

Publiciations >

Monthly Highlights >

Articles

Deals

Zhong Lun Assists MENA’s First QFII Asset Management Organization to Issue Chinese Securities Product

Zhong Lun Assists Yuan Kee Dumpling with First International Outlet Launch

Events

Awards

Zhong Lun Advises on Taimei’s IPO on the Main Board of The Stock Exchange of Hong Kong Limited